EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces a briefing for all investors to provide details of the successful fundraising and proposed AIM admission of Renalytix AI plc.
Today the Company announced a successful, conditional equity fundraising by its spin-out business, Renalytix AI plc.
EKF Diagnostics confirms equity fundraising.
EKF Diagnostics Holdings plc announces that a general meeting of the Company will be held on 19 October 2018.
EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2018.
EKF Diagnostics Holdings plc announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.
EKF to undertake further market soundings ahead of a prospective equity Fundraising by Renalytix AI and the admission of its shares to trading on AIM.
Standard form for notification of major holdings.
EKF Diagnostics provides shareholders with the following update on current trading.
EKF announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation – the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue – for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.